Medicine and Dentistry
Neoplasm
100%
Lung Cancer
72%
Non Small Cell Lung Cancer
47%
Radiation Therapy
39%
Malignant Neoplasm
38%
Computer Assisted Tomography
37%
Lung
37%
Diseases
32%
Cancer
31%
Metastatic Carcinoma
31%
Radiology
30%
Immunotherapy
25%
Positron Emission Tomography-Computed Tomography
24%
Cancer Staging
20%
Magnetic Resonance Imaging
20%
Immune Checkpoint Inhibitor
18%
Lung Nodule
16%
Overall Survival
16%
Pneumonia
16%
COVID-19
15%
Diagnosis
14%
Pulmonary Embolism
14%
Surgery
14%
Chemoradiotherapy
14%
Mediastinum Mass
13%
Chest
13%
Thorax Radiography
13%
Recurrent Disease
13%
Biological Marker
13%
Biopsy Technique
12%
Immunity
12%
Lung Cancer Screening
12%
Adverse Event
11%
Targeted Therapy
11%
Progression Free Survival
11%
Lung Metastasis
11%
Low Drug Dose
11%
Thymus Cancer
11%
Ipilimumab
11%
Pembrolizumab
10%
Thymic Carcinoma
10%
Pleura Mesothelioma
9%
Polyethylene Terephthalate
9%
Diagnostic Imaging
9%
Nivolumab
9%
Clinical Trial
9%
Phase II Trials
9%
Stereotactic Body Radiation Therapy
8%
Circulating Tumor DNA
8%
Adenocarcinoma
8%
Oncology
8%
Arm
8%
Esophageal Cancer
8%
Differential Diagnosis
8%
Hazard Ratio
7%
Cardiac Magnetic Resonance Imaging
7%
Lung Adenocarcinoma
7%
Venous Thromboembolism
7%
Randomized Clinical Trial
7%
Lymph Node
7%
Epidermal Growth Factor Receptor
6%
Odds Ratio
6%
Solid Malignant Neoplasm
6%
Thoracic Wall
6%
Selinexor
6%
Health Care
6%
Neuroendocrine Tumor
6%
Non-Small Cell Lung Cancer
6%
Esophagus Carcinoma
5%
Mesothelioma
5%
Infection
5%
Systemic Therapy
5%
Lobectomy
5%
Immune System
5%
Intensity Modulated Radiation Therapy
5%
Visceral Pleura
5%
Multimodality Imaging
5%
Epithelioma
5%
Small Cell Lung Cancer
5%
Keyphrases
Tumor
43%
Lung Cancer
40%
Non-small Cell Lung Cancer (NSCLC)
33%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
20%
Immune Checkpoint Inhibitors
17%
Positron Emission Tomography-computed Tomography (PET-CT)
16%
Radiologists
14%
Computed Tomography
14%
Overall Survival
14%
Pneumonitis
13%
In Cancer
13%
International Association for the Study of Lung Cancer (IASLC)
13%
Confidence Interval
12%
Selinexor
12%
Pearl
12%
Chemotherapy
12%
Lung Cancer Staging
12%
Programmed Death-ligand 1 (PD-L1)
12%
Single Center
11%
Targeted Therapy
11%
Multi-arm
11%
Phase II Trial
11%
Lung
11%
Advanced Solid Tumors
11%
Radiation Therapy
10%
Ipilimumab
10%
ACR Appropriateness Criteria
10%
Ninth Edition
10%
Phase II Study
10%
Thorax
9%
Cancer Patients
9%
Hazard Ratio
9%
Progression-free Survival
9%
Clinical Outcomes
9%
Adenocarcinoma
9%
Lung Cancer Screening
9%
Metastatic Disease
9%
Nivolumab
8%
Magnetic Resonance Imaging
8%
Misinterpretation
8%
Radiotherapy
8%
Metastatic Tumor
8%
Phase Ib Study
8%
Mediastinal Mass
8%
Thymic Carcinoma
8%
TNM Classification
8%
Imaging Findings
7%
Symptomatic Pulmonary Embolism
7%
Esophageal Cancer
7%
Pembrolizumab
7%
Stereotactic Body Radiation Therapy
7%
International Thymic Malignancy Interest Group (ITMIG)
7%
Median Progression-free Survival
7%
North America
7%
Thymic Epithelial Tumors
6%
Imaging Modalities
6%
Chemoradiation
6%
Carboplatin
6%
Randomized Clinical Trial
6%
Stereotactic Ablative Radiotherapy
6%
Neoplasms
6%
European American
6%
Low-dose Radiation
6%
Artificial Intelligence Ethics
6%
Artificial Intelligence
6%
Artificial Intelligence in Radiology
6%
Advanced or Metastatic
6%
Circulating Tumor DNA (ctDNA)
6%
Pulmonary Embolism
6%
Treatment-related Adverse Events
6%
Imaging Appearance
6%
Objective Response Rate
5%
Cancer Mortality
5%
Non-small Cell Lung Cancer Patients
5%
Malignancy
5%
Clinical Activity
5%
Early-stage Lung Cancer
5%
Differential Diagnosis
5%
Targeted Immunotherapy
5%
Mediastinal Compartments
5%
Tumor-node-metastasis Staging
5%
Abscopal Response
5%
Systemic Therapy
5%
Median Overall Survival
5%
Radiology
5%
Clinical Efficacy
5%
Imaging Characteristics
5%